Sanofi ADS$42.83REGN · NASDAQ-GS
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B |
| Cost of Revenue | — | — | — | — | — | — | $402.80M | $237.50M |
| Research & Development | $5.85B | $5.13B | $4.44B | $3.59B | $2.86B | $2.65B | $2.45B | $1.47B |
| Selling, General & Administrative | $2.70B | $2.95B | $2.63B | $2.12B | $1.82B | $1.35B | $1.34B | $1.13B |
| Operating Expenses | $10.77B | $10.21B | $9.07B | $7.43B | $7.12B | $4.92B | $4.35B | $2.61B |
| Operating Income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B |
| Interest Expense | — | — | $73.00M | $59.40M | $57.30M | $56.90M | $30.20M | $28.20M |
| Other Income / (Expense) | $1.65B | $789.20M | $152.20M | $119.90M | $379.00M | $233.80M | $219.30M | $19.10M |
| Income Before Taxes | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B | $3.81B | $2.43B | $2.55B |
| Provision for Income Taxes | $725.80M | $367.30M | $245.70M | $520.40M | $1.25B | $297.20M | $313.30M | $109.10M |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B |
| Basic EPS | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 |
| Diluted EPS | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 |
| Basic Shares Outstanding | 104.60M | 107.90M | 106.70M | 107.10M | 105.70M | 107.60M | 109.20M | 107.90M |
| Diluted Shares Outstanding | 108.60M | 115.10M | 113.70M | 113.50M | 112.20M | 115.10M | 114.60M | 114.80M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $38.64 | $32.42 | $48.29 | 9 | ↑2 ↓4 |
| Dec 2027 | $44.22 | $19.62 | $58.03 | 9 | ↑2 ↓3 |
| Dec 2028 | $46.72 | $42.89 | $50.54 | 2 | ↑1 ↓0 |
| Dec 2029 | $52.28 | $52.28 | $52.28 | 1 | ↑0 ↓0 |
